Yuyao People's Hospital
12
3
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Role: collaborator
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Role: collaborator
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Role: collaborator
A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts
Role: collaborator
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
Role: collaborator
Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer
Role: collaborator
Real-world Study of Efficacy and Safety of Zonisamide in add-on Therapy for Patients With Focal Epilepsy
Role: collaborator
Computer Scan Based Analysing System on Improving Stroke Management Quality Evaluation
Role: collaborator
Improving In-hospital Stroke Service Utilisation in China
Role: collaborator
Nutritional Status Study of Inpatients in Hospitals
Role: collaborator
Investigation on the Practice Status of Emergency Stuff
Role: collaborator
The Effect of Standardized Enteral Nutrition on Critically Ill Patients
Role: collaborator
All 12 trials loaded